This animal model study investigated a hyaluronic acid-based compound (hyaluronic acid-ethylenediamine-cinnamic acid) in diarrhea-predominant irritable bowel syndrome (IBS-D), examining three potential mechanisms: serotonin (5-hydroxytryptamine) signaling, intestinal barrier function, and gut microbiota composition. The compound demonstrated effects on all three pathways in the animal model, suggesting a multi-target mechanism of action. This is **animal model-level evidence** and would require human clinical investigation before applicability to patient populations.
For your business
Animal data suggests this HA compound may influence serotonin signaling, gut barrier, and microbiota in IBS-D; human trials needed before clinical application.
Read more on International journal of biological macromolecules →